Inhibikase Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Inhibikase Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Wilmington
- Headquarters state / province
- Delaware
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IKT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001750149
- EIN
- 26-3407249
Board of directors
-
Amit Munshi · DirectorSince 2024
-
Arvind Kush · DirectorSince 2024
-
David Canner · DirectorSince 2024
-
Dennis N. Berman · DirectorSince 2023
-
Gisele Dion · DirectorSince 2023
-
Mark T. Iwicki · Director · Chief Executive OfficerSince 2025
-
Milton H. Werner · Director · President and CEOSince 2023
-
Paul C. Grint · DirectorSince 2023
-
Roberto Bellini · DirectorSince 2024
-
Roy Lester Freeman · DirectorSince 2023
-
Vincent Aurentz · DirectorSince 2025
Chief executives
Milton H. Werner
· President and CEO
Dates unknown
Mark T. Iwicki
· Chief Executive Officer
Since February 2025
Director election results
Annual meeting of June 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
77.2%
-
84.6%
Board connections
3 of this board's directors also sit on 7 other boards.
- via Amit Munshi
- via Gisele Dion
- via Amit Munshi
- via Mark T. Iwicki
- via Mark T. Iwicki
- via Mark T. Iwicki
- via Amit Munshi
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,999,999
- 1 purchase by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 30, 2026 | Dennis N. Berman Director | Option exercise | +21,854 | $1.26 | $27,536 |
| Jul 29, 2026 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other | −18,030,000 | — | — |
| Feb 21, 2026 | Vincent Aurentz Director | Sold back to the company | −255,299 | — | — |
| Feb 21, 2026 | Christopher Cabell Officer (President & Head of R&D) | Sold back to the company | −338,282 | — | — |
| Feb 21, 2026 | Amit Munshi Director | Sold back to the company | −19,089 | — | — |
| Nov 21, 2025 | SANDS FRANK M. 10% owner | Open-market purchase | +2,068,965 | $1.45 | $2,999,999 |
| Feb 21, 2025 | Amit Munshi Director | Grant or award | +57,265 | — | — |
| Oct 21, 2024 | Roberto Bellini Director | Open-market purchase | +1,460,000 | $1.37 | $2,000,200 |
| Oct 21, 2024 | Arvind Kush Director | Open-market purchase | +145,000 | $1.37 | $198,650 |
| Oct 21, 2024 | Amit Munshi Director | Open-market purchase | +365,000 | $1.37 | $500,050 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.